Human ACE and bradykinin B 2 receptors form a complex at the plasma membrane
Authors:
Open Access
- 1 November 2006
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 20 (13) , 2261-2270
Abstract
To investigate how angiotensin I‐converting enzyme (ACE) inhibitors enhance the actions of bradykinin (BK) on B 2 receptors independent of blocking BK inactivation, we expressed human somatic ACE and B 2 receptors in CHO cells. Bradykinin and its ACE‐resistant analog were the receptor agonists. B 2 fused with green fluorescent protein (GFP) and ACE were coprecipitated with antisera to GFP or ACE shown in Western blots. Immunohistochemistry of fixed cells localized ACE by red color and B 2 ‐GFP by green. Yellow on plasma membranes of coexpressing cells also indicated enzyme‐receptor complex formation. Using ACE‐fused cyan fluorescent protein donor and B 2 ‐fused yellow fluorescent protein (YFP) acceptor, we registered fluorescence resonance energy transfer (FRET) by the enhanced fluorescence of donor on acceptor photobleaching, establishing close (within 10 nm) positions of B 2 receptors and ACE. Bradykinin stimulation cointernalized ACE and B 2 receptors. We expressed ACE fused to N terminus of B 2 receptors, anchoring only receptors to plasma membranes. Here, in contrast to cells, where both ACE and B 2 receptors are separately anchored, ACE inhibitors neither enhance activation of chimeric B 2 nor resensitize desensitized B 2 receptors. Heterodimer formation between ACE and B 2 receptors can be a mechanism for ACE inhibitors to augment kinin activity at cellular level.—Chen, Z., Deddish, P. A., Minshall, R. D., Becker, R. P., Erdös, E. G., Tan, F. Human ACE and bradykinin B2 receptors form a complex at the plasma membrane. FASEB J. 20, 2261–2270 (2006)Keywords
Funding Information
- National Institutes of Health (HL36473, HL68580)
This publication has 49 references indexed in Scilit:
- Angiotensin I-Converting Enzyme Inhibitors Block Protein Kinase Cϵ by Activating Bradykinin B1 Receptors in Human Endothelial CellsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Hydrolysis of Angiotensin Peptides by Human Angiotensin I–Converting Enzyme and the Resensitization of B 2 Kinin ReceptorsHypertension, 2005
- Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic studyAmerican Heart Journal, 2005
- Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP9αPeptides, 2005
- Signaling via the Angiotensin-Converting Enzyme Enhances the Expression of Cyclooxygenase-2 in Endothelial CellsHypertension, 2005
- Novel Mode of Action of Angiotensin I Converting Enzyme InhibitorsJournal of Biological Chemistry, 2002
- Neprilysin Inhibitors Potentiate Effects of Bradykinin on B2 ReceptorHypertension, 2002
- Enhancement of Bradykinin and Resensitization of Its B2ReceptorHypertension, 1999
- Human Converting EnzymeClinical and Experimental Hypertension. Part A: Theory and Practice, 1983
- Angiotensin converting enzyme inhibition in patients with congestive heart failure.Circulation, 1978